NFKB1 and head and neck squamous cell carcinoma: A recent study reported that specific EGFR tyrosine kinase inhibitor erlotinib induce IL-6 expression in head and neck squamous cell carcinoma through NOX4/p38 and JNK/ NF-κB pathway [28, 56].